E
Viridian Therapeutics, Inc. VRDN
$18.02 -$0.12-0.66% NASDAQ
Recommendation
Prev Close
$17.81
Volume
668,819
Avg Vol (90D)
801,077
Market Cap
$1.45B
Dividend & Yield
--
52-Week Range
$9.90 - $27.20
P/E (TTM)
--
EPS (TTM)
-$3.26
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Will Viridian Therapeutics' (VRDN) Expanded Losses and Shelf Registration Reshape Its Capital Strategy?
8/17/2025 - Simply Wall St
9 Best Small Cap Stocks with Biggest Upside Potential
8/17/2025 - Insider Monkey
How The Parts Add Up: SCHB Headed For $27
8/14/2025 - ETF Channel
Viridian Therapeutics (VRDN, $18.85) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 13, 2025
8/14/2025 - Tickeron - Stocks
Viridian Therapeutics (VRDN, $17.97) entered Uptrend as Momentum indicator ascends above 0 level on Aug 12, 2025
8/13/2025 - Tickeron - Stocks
Widening Losses and Shelf Registration Could Be a Game Changer For Viridian Therapeutics (VRDN)
8/13/2025 - Simply Wall St
HC Wainwright Issues Optimistic Estimate for VRDN Earnings
8/11/2025 - MarketBeat
Lifesci Capital Has Negative Estimate for VRDN Q3 Earnings
8/11/2025 - MarketBeat
Leerink Partnrs Issues Optimistic Outlook for VRDN Earnings
8/11/2025 - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for VRDN
8/11/2025 - MarketBeat
Wedbush Lowers Earnings Estimates for Viridian Therapeutics
8/9/2025 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Hits Expectations
8/9/2025 - MarketBeat
Royal Bank Of Canada Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
8/9/2025 - Ticker Report
The Goldman Sachs Group Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
8/8/2025 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $41.00 at Royal Bank Of Canada
8/8/2025 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $26.00 at Wells Fargo & Company
8/8/2025 - MarketBeat
Oppenheimer Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00
8/8/2025 - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages
8/8/2025 - Ticker Report
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $34.00
8/7/2025 - MarketBeat
Goldman Sachs Raises Price Target for Viridian Therapeutics (VRDN) to $30 VRDN Stock News
8/7/2025 - GuruFocus
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
8/7/2025 - Benzinga
RBC Capital Remains a Buy on Viridian Therapeutics (VRDN)
8/7/2025 - TipRanks Financial Blog
Wells Fargo Adjusts Price Target for Viridian Therapeutics (VRDN) on August 7, 2025 VRDN ...
8/7/2025 - GuruFocus
Viridian Therapeutics (VRDN) Analyst Rating Update: Target Price Raised by Oppenheimer VRDN ...
8/7/2025 - GuruFocus
Viridian Therapeutics price target raised by $4 at Oppenheimer, here's why
8/7/2025 - The Fly
Income Statement
Total Revenue (TTM)
$305.00K
EBITDA (TTM)
-$371.10M
EBIT (TTM)
-$371.59M
Net Income (TTM)
-$344.06M
Balance Sheet
Total Assets (Q)
$582.32M
Total Debt (Q)
$23.08M
Total Liabilities (Q)
$67.16M
Book Value Per Share (Q)
$4.00
Cash Flow
Cash from Operations (TTM)
-$309.06M
Cash from Investing (TTM)
$28.20M
Cash from Financing (TTM)
$290.52M
Net Change in Cash (TTM)
$9.66M
Filings
Filing Date
Wednesday, August 6, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.46
7-Day Total Return
0.28%
30-Day Total Return
5.20%
60-Day Total Return
29.36%
90-Day Total Return
49.92%
Year to Date Total Return
-8.81%
1-Year Total Return
15.66%
2-Year Total Return
-9.40%
3-Year Total Return
-24.22%
5-Year Total Return
12.27%
52-week Low
Apr 09, 2025 - $9.90
52-week High
Nov 12, 2024 - $27.20
Valuation
Market Cap
$1.45B - Small Cap
Enterprise Value
$1.10B
Price/Sales (TTM)
4,813.51
Price/Book (Q)
4.46
Dividends and Shares
Shares Outstanding
81.59
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.viridiantherapeutics.com
Phone Number
617 272 4600
Address
221 Crescent Street
Waltham, MA 02453
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal... more
NASDAQ 08/21/2025 4:00PM Eastern Quotes delayed